Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

HCW ups Cesca Therapeutics PT to $6.50 from $1

H.C. Wainwright raised its price target for Cesca Therapeutics (NASDAQ:KOOL) to $6.50 from $1 after the company’s second quarter revenue beat consensus. The stock closed at $3 on Aug. 13. Cesca develops and markets...

August 14, 2019

Markets

HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12. Analyst Joseph Pantginis writes that Mustang is developing multiple novel...

August 13, 2019

Markets

Piper cuts Ra Medical to neutral; PT to $1.50 from $9

Piper Jaffray downgraded Ra Medical Systems (NASDAQ:RMED) to “neutral” from “overweight” and slashed its price target to $1.50 from $9 after the company disclosed several operating issues in its preliminary second...

August 13, 2019

Markets

SVB Leerink starts Fulcrum Therapeutics at OP; PT $20

SVB Leerink initiated coverage of Fulcrum Therapeutics (NASDAQ:FULC) with an “outperform” rating and price target of $20 in 12 months. The stock closed at $11.62 on Aug. 9. Fulcrum is a clinical-stage biopharmaceutical...

August 12, 2019

Markets

HCW cuts Melinta Therapeutics to neutral and removes PT

H.C. Wainwright downgraded Melinda Therapeutics (NASDAQ:MLNT) to “neutral” from “buy” and removed its price target after the company’s chairman and CEO abruptly resigned on Aug. 9, when the stock dropped 67 cents to...

August 12, 2019

Markets

WB starts Phreesia at OP

William Blair launched coverage of Phreesia (NYSE:PHR) with an “outperform” rating. The stock closed at $27.37 on Aug. 9. Phreesia, which went public in July 2019, gives healthcare organizations a suite of robust...

August 12, 2019

Markets

HCW cuts Autolus PT to $24 from $41

H.C. Wainwright lowered its price target for Autolus Therapeutics plc (NASDAQ:AUTL) to $24 from $41 after significant changes to its pipeline and timelines were disclosed in the company’s second quarter results. The...

August 12, 2019

Markets

BTIG starts Precision BioSciences at buy; PT $22

BTIG initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $22 price target, representing upside of approximately 100% from a closing price of $10.98 on Aug. 8. “While Precision only recently...

August 9, 2019

Markets

BTIG cuts ViewRay PT to $6 from $10

BTIG lowered its price target for ViewRay (NASDAQ:VRAY) to $6 from $10 after the company reported second quarter results. The stock closed at $6.74 on Aug. 8 but was down to $3.35 in after hours trading. ViewRay, which...

August 9, 2019

Markets

WB starts Addus HomeCare at OP

William Blair initiated coverage of Addus HomeCare (NASDAQ:ADUS) with an “outperform” rating, saying the company is one of the few ways for public market investors to play the in-home healthcare delivery theme, with a...

August 9, 2019

Markets

BTIG starts Cellectis at buy; PT $37

BTIG launched coverage of Cellectis SA (NASDAQ:CLLS; Euronext Growth:ALCLS) with a “buy” rating and $37 price target. The stock closed at $13.86 on Aug. 8. “Despite the initial positive reaction from investors to...

August 9, 2019

Markets

HCW cuts Organovo to neutral and removes PT

H.C. Wainwright downgraded Organovo Holdings (NASDAQ:ONVO) to “neutral” from “buy” and removed its price target after the company engaged a financial advisor to assist management in exploring strategic alternatives. The...

August 8, 2019

Markets

Stifel cuts Inogen to hold; PT to $48 from $85

Stifel downgraded Inogen (NASDAQ:INGN) to “hold” from “buy” and lowered its price target to $48 from $85 after the company’s second quarter sales missed consensus estimates and it reduced 2019 guidance. The stock closed...

August 8, 2019

Markets

BTIG halves TransEnterix PT to $1.50 from $3

BTIG halved its price target for TransEnterix (NASDAQ:TRXC) to $1.50 from $3 after the company’s second quarter results fell short of guidance and consensus estimates. The stock closed at $1.15 on Aug. 7. TransEnterix...

August 8, 2019

Markets

HCW cuts Rexahn Pharma to neutral; PT to $3 from $23

H.C. Wainwright downgraded Rexahn Pharmaceuticals (NASDAQ:REXN) to “neutral” from “buy” and slashed its price target to $3 from $23 after a disappointing update from the company’s Phase 2a pancreatic cancer study...

August 8, 2019

Markets

WB starts Actinium Pharma at OP

William Blair launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with an “outperform” rating based on its view that the company’s potent and specific radiopharmaceuticals for improving treatment options of...

August 8, 2019

Markets

WB cuts AxoGen to MP from OP

William Blair downgraded AxoGen (NASDAQ:AXGN) to “market perform” from “outperform” after the company reduced revenue guidance for 2019. The stock closed at $17.58 on Aug. 6, near the low end of its 52-week range of $14...

August 7, 2019

Markets

BTIG ups Tactile Systems to buy with $62 PT

BTIG upgraded Tactile Systems Technology (NASDAQ:TCMD) to “buy” from “neutral” with a price target of $62. The stock closed at $49.30 on Aug. 6. Tactile Medical is a leader in developing and marketing at-home therapy...

August 7, 2019

Markets

Piper starts Alphatec at OW; PT $7

Piper Jaffray launched coverage of Alphatec Holdings (NASDAQ:ATEC) with an “overweight” rating and $7 price target. The stock closed at $4.80 on Aug. 2. Alphatec is a pure play spine provider that is introducing a...

August 5, 2019

Markets

HCW starts MediWound at buy; PT $5.50

H.C. Wainwright initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and price target of $5.50. The stock closed at $2.58 on Aug. 2. MediWound is developing proteolytic enzyme-based eschar debridement...

August 5, 2019

Markets

Piper cuts Intersect ENT to neutral; PT to $17 from $30

Piper Jaffray downgraded Intersect ENT (NASDAQ:XENT) to “neutral” from “overweight” and slashed its price target to $17 from $30 after the company reported second quarter results and lowered its revenue guidance to flat...

August 2, 2019

Markets

AGP cuts T2 Biosystems to neutral; PT 40 cents

Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” with a price target of 40 cents after the company reported second quarter results. The stock closed at 59 cents on Aug. 1. The...

August 2, 2019

Subscribe